Samumed Stock

Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. Founded in San Diego, California in 2008, Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.